# Quantitative Trading Public Research

Iterative research-driven quantitative strategy discovery.

## Repository Layout

- `PROMPT.MD` — mission and operating instructions
- `src/` — Python code
  - `data.py` — yfinance data acquisition + parquet caching
  - `backtest.py` — walk-forward engine, execution modeling, metrics
  - `strategies.py` — signal generators
  - `run_experiment.py` — single-strategy runner
  - `batch_run.py` — all-strategies comparison table
  - `validate.py` — placebo/null distribution + statistical checks
- `experiments/` — JSON results per strategy + summary
- `ledger/` — research ledger and prioritization procedure
- `data/` — parquet caches (gitignored)

## Quick Start

```bash
pip install yfinance pandas numpy scipy pyarrow
python3 src/batch_run.py        # run all strategies, print comparison
python3 src/validate.py         # placebo validation + statistical checks
```

## Key Findings (v1.1 - Broad Equity Universe)

| Strategy | OOS Sharpe | z vs Placebo | Positive Folds |
|---|---|---|---|
| **time_series_momentum (12m, 21d, inv-vol)** | **2.141** | **40.84** | **32/42** |
| reversal (12-month, 10d) | 2.288 | 29.46 | 34/42 |
| reversal (12-month, daily) | 2.103 | 29.46 | 34/42 |
| low_vol | 1.748 | 33.38 | 34/42 |
| quality (low-vol+mom) | 1.523 | 30.75 | 33/42 |
| momentum_6m | 1.335 | 30.85 | 30/42 |
| momentum (12m) | 1.248 | 29.30 | 31/42 |
| value | 1.120 | 24.82 | 24/42 |
| short_reversal | 0.776 | 21.10 | 25/42 |
| mean_reversion_5 | 0.087 | 18.03 | 26/42 |
| **random (placebo)** | **-0.656** | — | 0/50 |

Placebo baseline (50 random sims) has mean Sharpe **-0.656**. All strategies clear placebo with large z-scores. Results on 132 large-liquid US equities (2014-2026), walk-forward OOS.

## Caveats

- Single data source (yfinance); results on 132 large-liquid US equities (v1.1). Previous v1.0 used ETF-only universe.
- `auto_adjust=True` merges open/close adjustments; open-price execution is approximate.
- No parameter optimization yet — all signals use fixed, literature-standard parameters.
- Survivorship bias and delisting effects may not be fully captured by yfinance.
- Results are not independently validated against alternative data or brokers.

### Market-Neutral Discovery (E012 - large_liquid, walk-forward OOS)

All strategies tested prior to E012 were long-only equity-beta (+signal) and
correlated with SPY. E012 introduced the first genuinely market-neutral tests:
Betting Against Beta (Frazzini & Pedersen 2014) and a dollar-neutral low-beta sort.

| Strategy | OOS Sharpe | z vs Placebo | β vs SPY | Turnover | 2020-COVID Sharpe |
|---|---|---|---|---|---|
| **dollar-neutral low-beta (10/10, 21d)** | **1.287** | **7.78** | -0.035 | 0.064 | +1.440 |
| BAB (beta-neutral, canonical) | -0.629 | -0.67 | -0.003 | 0.041 | -4.239 |
| random (market-neutral placebo) | -0.477 | — | — | — | — |

- The **dollar-neutral low-beta sort** is the repository's first market-neutral strategy
  that is both beta-neutral (|β|<0.05, corr SPY ≈ -0.03) AND profitable (z=7.78). It complements
  the long-only `low_vol` factor (Sharpe 1.75, β≈0.7) by adding market-neutrality.
- The **canonical BAB factor** is market-neutral by construction but is negative on
  2014-2026 (OOS Sharpe -0.629, below the random market-neutral placebo) and collapses
  in the 2020 funding shock (Sharpe -4.24). Recorded as a rejected, regime-dependent candidate.
- Placebo baseline (50 random dollar-neutral sims): mean Sharpe -0.477.

### E013: Validation of the Dollar-Neutral Low-Beta Keeper

The keeper passed all gates (Sharpe ≥0.8, z ≥3, |β| ≤0.2) and survives realistic
shorting-cost stress:

| Parameter | Value |
|---|---|
| OOS Sharpe (baseline 252d/0.5/10pct) | 1.287 |
| Placebo z-score | 7.10 |
| Equity beta vs SPY | -0.035 |
| Corr vs SPY | -0.032 |
| Sharpe at 5bps round cost | 0.812 (still passes gate) |
| Sharpe at 0bps cost | 1.310 |

- **Beta-window sensitivity**: Sharpe robust across 63/126/252-day windows (1.18–1.29);
  252d optimal with lowest turnover (0.064). Shrink level (0.25/0.5/0.75) has no effect
  (rankings invariant to monotonic shrink).
- **Top-frac grid**: Sharpe improves as top_frac shrinks (0.05→1.48, 0.10→1.29, 0.15→1.15,
  0.20→1.11); default 0.10 retained as breadth-stable tradeoff.
- **Out-of-universe**: passes on 132-stock equity universe (1.287) and 10-stock ETF universe
  (0.877); fails on 10-name equity subset (0.680) — requires breadth for beta ranking.
- **Leg decomposition**: long low-beta leg Sharpe=1.744 (β=-0.096); short high-beta leg
  Sharpe=-1.621 (β=0.061) — net profit from long leg offsetting short losses, maintaining zero beta.

### Net-of-Cost Performance (large_liquid, walk-forward OOS)

The existing table follows.

| Strategy | Turnover (daily) | Base (0.5bps+0.2bps) | High (20bps+5bps) |
|---|---|---|---|
| **time_series_momentum (21d, inv-vol)** | **0.013** | **2.14** | **2.04** |
| reversal (10d) | 0.028 | 2.29 | 1.92 |
| reversal (daily) | 0.09 | 2.10 | 1.64 |
| low_vol | 0.05 | 1.75 | 1.55 |
| momentum_6m | 0.14 | 1.34 | 0.56 |
| quality | 0.30 | 1.52 | 0.29 |
| momentum | 0.44 | 1.25 | -0.92 |

Cost-robustness: **time_series_momentum** and low_vol/reversal survive high costs best. High-turnover strategies degrade sharply. TSM is the most cost-robust (4.7% Sharpe drop at 20bps+5bps vs 22% for reversal).

## Status

- `src/`: `data.py`, `backtest.py`, `strategies.py`, `run_experiment.py`, `batch_run.py`, `validate.py`, `validation.py`.
- New in E012: `strategies.beta_factor`, `backtest.bab_weights`, `backtest.dollar_neutral_longshort_weights`, driver `experiments/run_e012.py`. See `ledger/RESEARCH_LEDGER.md` (E001-E013).
- New in E013: `strategies.dollar_neutral_lowbeta` signal, market-neutral CLI path in `run_experiment.py`, driver `experiments/run_e013.py`.
- `data.py`: added retry logic for yfinance downloads (cache-read failure no longer silently falls through to flaky download).
- Run all baseline strategies: `python3 src/batch_run.py --universe large_liquid`
- Run placebo validation: `python3 src/validate.py --universe large_liquid`
- Run market-neutral experiment: `python3 experiments/run_e012.py`
- Run keeper validation: `python3 experiments/run_e013.py`
- Run market-neutral strategy via CLI: `python3 -m src.run_experiment dollar_neutral_lowbeta --universe large_liquid`
- Next task (E014): build portfolio combining the keeper with long-only TSM/reversal (beta-neutral overlay on top of high-Sharpe long-only signals).
